News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Suitors Eye Novartis AG (NVS)'s Vaccines Business


2/5/2014 7:01:01 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Novartis AG (NOVN) is drawing interest from potential bidders for its human-vaccines unit as talks to swap its animal-health business for assets from Merck & Co. (MRK) slow down, people with knowledge of the matter said. While the vaccines unit was initially on the table with animal health as part of the possible trade for Merck’s over-the-counter drugs business, Novartis may now sell vaccines separately, said three of the people, who asked not to be named because the process is private. The business could be valued at about $1 billion, one of the people said.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg


comments powered by Disqus
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES